Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Clinical trial NCT05619536 · COMPLETED
Trial details
- NCT number
- NCT05619536
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-18
- Primary completion
- 2023-07-14
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.